Clinical efficacy and safety of dotinurad, a novel selective urate reabsorption inhibitor, in Japanese hyperuricemic patients with or without gout: randomized, multicenter, double-blind, placebo-controlled, parallel-group, confirmatory phase 2 study

ConclusionThe serum uric acid lowering effect and safety of dotinurad were confirmed in hyperuricemic patients with or without gout.ClinicalTrials.gov IdentifierNCT02416167

http://link.springer.com/10.1007/s10157-019-01818-2

Source: Clinical and Experimental Nephrology - December 2, 2019 Category: Urology & Nephrology Source Type: research